Activity and toxicity of GI147211 in breast, colorectal and non-small-cell lung cancer patients: An EORTC-ECSG phase II clinical study
dc.contributor.author | Gamucci, T. | en |
dc.contributor.author | Paridaens, R. | en |
dc.contributor.author | Heinrich, B. | en |
dc.contributor.author | Schellens, J. H. M. | en |
dc.contributor.author | Pavlidis, Nicholas | en |
dc.contributor.author | Verweij, J. | en |
dc.contributor.author | Sessa, Cristiana | en |
dc.contributor.author | Kaye, Stanley B. | en |
dc.contributor.author | Roelvink, M. | en |
dc.contributor.author | Wanders, J. | en |
dc.contributor.author | Hanauske, A. R. | en |
dc.creator | Gamucci, T. | en |
dc.creator | Paridaens, R. | en |
dc.creator | Heinrich, B. | en |
dc.creator | Schellens, J. H. M. | en |
dc.creator | Pavlidis, Nicholas | en |
dc.creator | Verweij, J. | en |
dc.creator | Sessa, Cristiana | en |
dc.creator | Kaye, Stanley B. | en |
dc.creator | Roelvink, M. | en |
dc.creator | Wanders, J. | en |
dc.creator | Hanauske, A. R. | en |
dc.date.accessioned | 2018-06-22T09:53:11Z | |
dc.date.available | 2018-06-22T09:53:11Z | |
dc.date.issued | 2000 | |
dc.identifier.uri | https://gnosis.library.ucy.ac.cy/handle/7/41700 | |
dc.description.abstract | Background: GI147211 is a water-soluble synthetic analogue of camptothecin showing promising in vivo and in vitro antitumor activity and an acceptable toxicity profile. Patients and methods: Between April 1995 and November 1996, 67 eligible patients with pretreated breast cancer (25 patients) and chemo-naive colorectal (19 patients) and non-small-cell lung cancer (23 patients) were entered into three multicentric, non-randomized phase II trials. Treatment schedule consisted of intravenous GI147211 administered at a dose of 1.2 mg/m2/day for five consecutive days every three weeks. Results: Hematological toxicity was common with grade 3-4 neutropenia in 54% of patients and neutropenic fever together or not associated with infection in 14.5% of patients. Grade 3-4 thrombocytopenia and grade 2-4 anemia were observed in 20% and in 68% of patients, respectively. Non-hematological toxicity was generally mild to moderate and consisted mainly of gastrointestinal toxicity, asthenia and alopecia. A dose-escalation to 1.5 mg/m2/d was feasible in 17 (25%) patients. The antitumor activity of GI147211 was moderate in breast cancer patients (3 partial responses (PRs), response rate (RR) 13%) and minimal in non-small cell lung cancer patients (2 PRs, RR 9%). No objective responses were obtained in colorectal patients. Conclusions: GI147211, at the dose and schedule employed in this study, showed an acceptable safety profile but a modest antitumor activity in the examined tumor types. | en |
dc.language.iso | eng | en |
dc.source | Annals of Oncology | en |
dc.subject | Article | en |
dc.subject | Antineoplastic agents | en |
dc.subject | Cancer chemotherapy | en |
dc.subject | Human | en |
dc.subject | Humans | en |
dc.subject | Adult | en |
dc.subject | Aged | en |
dc.subject | Breast neoplasms | en |
dc.subject | Female | en |
dc.subject | Middle aged | en |
dc.subject | Drug response | en |
dc.subject | Priority journal | en |
dc.subject | Alopecia | en |
dc.subject | Anemia | en |
dc.subject | Clinical article | en |
dc.subject | Clinical trial | en |
dc.subject | Febrile neutropenia | en |
dc.subject | Multicenter study | en |
dc.subject | Neutropenia | en |
dc.subject | Phase 2 clinical trial | en |
dc.subject | Thrombocytopenia | en |
dc.subject | Antineoplastic activity | en |
dc.subject | Infusions | en |
dc.subject | Intravenous | en |
dc.subject | Treatment outcome | en |
dc.subject | Lung neoplasms | en |
dc.subject | Lung non small cell cancer | en |
dc.subject | Dose response | en |
dc.subject | Dose-response relationship | en |
dc.subject | Drug | en |
dc.subject | Carcinoma | en |
dc.subject | Male | en |
dc.subject | Gastrointestinal symptom | en |
dc.subject | Breast cancer | en |
dc.subject | Colorectal cancer | en |
dc.subject | Colorectal neoplasms | en |
dc.subject | Camptothecin | en |
dc.subject | Asthenia | en |
dc.subject | Non-small-cell lung | en |
dc.subject | Camptothecin derivative | en |
dc.subject | Camptothecins | en |
dc.subject | Gi147211 | en |
dc.subject | Lurtotecan | en |
dc.subject | Non-small-cell lung cancer | en |
dc.subject | Topoisomerase i | en |
dc.title | Activity and toxicity of GI147211 in breast, colorectal and non-small-cell lung cancer patients: An EORTC-ECSG phase II clinical study | en |
dc.type | info:eu-repo/semantics/article | |
dc.identifier.doi | 10.1023/A:1008373031714 | |
dc.description.volume | 11 | |
dc.description.issue | 7 | |
dc.description.startingpage | 793 | |
dc.description.endingpage | 797 | |
dc.author.faculty | Ιατρική Σχολή / Medical School | |
dc.author.department | Ιατρική Σχολή / Medical School | |
dc.type.uhtype | Article | en |
dc.contributor.orcid | Pavlidis, Nicholas [0000-0002-2195-9961] | |
dc.gnosis.orcid | 0000-0002-2195-9961 |
Files in this item
Files | Size | Format | View |
---|---|---|---|
There are no files associated with this item. |